The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer
Molecular profiling has revolutionized the diagnosis and management of patients with non-small cell lung cancer (NSCLC), enabling personalized treatment approaches that have significantly improved patient outcomes. Identifying specific gene mutations and protein expression profiles guides therapeutic decisions and has become standard in the management of patients with NSCLC. Multiple organizations have published guidelines for biomarker testing. However, differences in the timing, methodology, and scope of recommended targets create potential for inconsistencies in clinical practice. This article reviews the clinical importance of biomarker testing in NSCLC, compares major guidelines, and highlights the challenges and implications of guideline variability in formulating recommendations on biomarker testing for patients with NSCLC.
Authors
- Robert D. Suh (ORCID: https://orcid.org/0000-0001-7872-9967)
- Bart Singer (ORCID: https://orcid.org/0000-0001-5016-3340)
- Jonathan L. Heald
- Farhood Farjah (ORCID: https://orcid.org/0000-0002-5205-3804)
- Ignacio I. Wistuba (ORCID: https://orcid.org/0000-0003-3365-6340)
- George A. Eapen (ORCID: https://orcid.org/0000-0001-6408-6964)
- Lynette Scholl
- Raymond U. Osarogiagbon
- Haresh Mani
- Shetal A. Patel
- Robert A. Smith (ORCID: https://orcid.org/0000-0003-3344-2238)
- M. Patricia Rivera (ORCID: https://orcid.org/0000-0003-3827-5010)
- Douglas Wood
- Edward S. Kim
- Gerard A. Silvestri
- Karen Kelly
- Terri A. DiJulio
- Bruce E. Johnson
- Michael Nead
- Jasleen K. Pannu
- Catherine R. Sears
- Nicholas J. Pastis
Institutions
- University of North Carolina at Chapel Hill (US)
- American Cancer Society (US)
- City Of Hope National Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Medical University of South Carolina (US)
- University of California, Los Angeles (US)
- University of Washington (US)
- Infectious Diseases Society of America (US)
- Inova Fairfax Hospital (US)
- The Ohio State University Wexner Medical Center (US)
- University of Rochester Medical Center (US)
- Moffitt Cancer Center (US)
- Baptist Cancer Center (US)
- Richard L. Roudebush VA Medical Center (US)
- Dana-Farber Cancer Institute (US)
- Go2 for Lung Cancer (US)
- International Association for the Study of Lung Cancer (US)
- UNC Lineberger Comprehensive Cancer Center
- Indiana University – Purdue University Indianapolis (US)
- University of California, Davis (US)
Publication Details
- Journal
- Cancer
- Published
- 2026-05-12
- DOI
- https://doi.org/10.1002/cncr.70384
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00